NICE National Institute for Health and Care Excellence

NICE guidance

Elotuzumab for previously treated multiple myeloma (terminated appraisal)

Technology appraisal guidance
Published: 22 March 2017

www.nice.org.uk/guidance/ta434

Contents

Advice

NICE is unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was received from Bristol–Myers Squibb for the technology.

Background

Bristol–Myers Squibb was invited to submit evidence for this single technology appraisal for elotuzumab in December 2015.

Elotuzumab is used in combination with lenalidomide and dexamethasone. The ELOQUENT-2 clinical trial showed a favourable efficacy and safety profile of this regimen compared with lenalidomide plus dexamethasone.

The company was unable to show that the additional survival benefit or the improvements in quality of life associated with this combination were sufficient to warrant the increased cost to the NHS of funding all 3 drugs, as determined by the NICE cost-effectiveness threshold.

NICE has therefore terminated this single technology appraisal.

Information

NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of elotuzumab for previously treated multiple myeloma. If, after doing this, organisations still wish to consider elotuzumab for previously treated multiple myeloma, they should follow the advice on rational local decision-making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, which outlines the approach that should be adopted in circumstances in which NICE guidance is unavailable.

NICE will review the position at any point if the company indicates that it wishes to make a full submission.

ISBN: 978-1-4731-2420-2